Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance (Form 8-K)

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

SALT LAKE CITY, January 12, 2026 - Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2025, and provided full year 2026 financial guidance.

These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the Myriad Genetics website at investor.myriad.com on Wednesday, January 14, 2026 at 5:15 pm PT (8:15 pm ET) in connection with the company's presentation at the 44th Annual J.P. Morgan Healthcare Conference. 

Select Preliminary Fourth Quarter and Full Year 2025 Financial Results 

The company expects the following: 

•Fourth quarter of 2025 total revenues to be between $207 million and $209 million,

•Full year 2025 total revenues to be between $822 million to $824 million.

The company plans to release its actual financial results for the fourth quarter and full year 2025 during its earnings call to be held in February 2026.

The select financial results for the quarter and full year ended December 31, 2025 set forth in this press release are preliminary and subject to Myriad Genetics' normal quarter and year-end accounting procedures and external audit by the company's independent registered public accounting firm. As a result, these select preliminary, unaudited financial results may change in connection with the finalization of the company's year-end closing and reporting processes and financial statements for the quarter and full year ended December 31, 2025 and may not represent the actual financial results for the quarter and full year ended December 31, 2025. In addition, these select preliminary, unaudited financial results are not a comprehensive statement of the company's financial results for the year ended December 31, 2025, should not be viewed as a substitute for full, audited financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP), and are not necessarily indicative of the company's results for any future period. 

1

2026 Financial Guidance

Myriad Genetics does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, strategic realignment, certain litigation charges and loss contingencies, costs related to acquisitions/divestitures and the related amortization, impairment and related charges, depreciation, equity compensation, tax benefits and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the company's stock price. Any associated estimate of these items and their impact on GAAP performance could vary materially. 

The company introduces the full year 2026 financial guidance in the table below*

(in millions, except percentages)

Guidance

Comments

Revenue

$860 - $880

The mid-point of the 2026 revenue guidance range reflects an increase of approximately 6% compared to the mid-point of the preliminary 2025 revenue range.

Adjusted Gross Margin **

68% - 69%

This range incorporates the anticipated impact from new product launches.

Adjusted EBITDA***

$37 - $49

The mid-point of the adjusted EBITDA range is expected to grow approximately 43% over the mid-point of the previous full year 2025 guidance range.

*

Assumes currency rates as of January 12, 2026.

**

Adjusted Gross Margin is defined as Gross Margin plus non-cash cost of sales, such as amortization of intangible assets and share-based compensation expense, and non-recurring one-time expenses.

***

Adjusted EBITDA is defined as Net Income (loss) plus income tax expense (benefit), total other income (expense), non-cash operating expenses, such as amortization of intangible assets, depreciation, impairment of long-lived assets, and share-based compensation expense, and one-time expenses such as expenses from strategic realignment, legal settlements, and divestitures and acquisitions.

These projections are forward-looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release. 

2

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Statement regarding use of non-GAAP financial measures

In this press release, the company's 2026 financial guidance is provided in accordance with GAAP and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the company's business. The company does not forecast GAAP gross margin or GAAP EBITDA because it cannot predict certain elements that are included in reported GAAP results. Please see above under "2026 Financial Guidance" for a full explanation.

The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, if available, to more fully understand its business. Non-GAAP financial results are reported in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

3